Jay R. Luly - Dec 19, 2022 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Role
President and CEO, Director
Signature
/s/ Nathaniel S. Gardiner as attorney-in-fact
Stock symbol
ENTA
Transactions as of
Dec 19, 2022
Transactions value $
$399,910
Form type
4
Date filed
12/19/2022, 06:50 PM
Previous filing
Dec 16, 2022
Next filing
Feb 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ENTA Common Stock Options Exercise $400K +14.5K +1.87% $27.58 788K Dec 19, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ENTA Stock Option (Right to Buy) Options Exercise $0 -14.5K -20.71% $0.00 55.5K Dec 19, 2022 Common Stock 14.5K $27.58 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 100% of the shares subject to the option are fully vested and exercisable.